Clinical Trial Update: Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update describes using proteoMICS to identify biomarkers of organ damage and response to mepolizumab in eosinophilic granulomatosis wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Asthma
• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Nucala (mepolizumab)

Snippet

Sponsor: Azienda Ospedaliero Universitaria di Cagliari | Conditions: EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Status: ENROLLING_BY_INVITATION